Plain-English translation of NCT06270316 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage clinical trial testing , a gene therapy designed to help your body produce an enzyme called α-galactosidase A, which is missing or deficient in Fabry disease. The medication is delivered through a single intravenous infusion and works by targeting your liver to produce the enzyme your body needs. Researchers will test three different dose levels to find the safest and most effective amount.
Current Fabry disease treatments help some patients, but many people still experience ongoing pain, digestive problems, and other symptoms despite taking enzyme replacement therapy. This trial exists to see whether the new treatment can help patients who have not fully responded to existing therapies.
You likely qualify if…
You likely don't qualify if…
You will receive a single intravenous infusion of the medication at one of three dose levels. After that, you will have regular follow-up visits at the study site that include blood tests, imaging scans, questionnaires, and other assessments to monitor your safety and how well the treatment is working. You cannot receive any vaccinations for 6 weeks before and 6 weeks after your infusion. The study will track your symptoms and disease markers over time to see if the treatment helps reduce your pain, digestive problems, and other Fabry disease symptoms.
AI-generated summary from trial data · Oct 3, 2026 · Not medical advice
United States